Intellia's in vivo CRISPR therapy lonvo-z meets Phase 3 HAELO endpoints and launches rolling BLA submission

Top three-source perspective and TSO verification:

• Source 1 is the company press release, which explicitly states that lonvo-z (formerly NTLA-2002) achieved positive topline results in the global Phase 3 HAELO trial, meeting the primary endpoint and all key secondary endpoints, and that a rolling BLA submission with the FDA has begun.

• Source 2 is an industry media report confirming that the in vivo gene-editing therapy lonvo-z met the primary endpoint in Phase 3, prompting the company to begin a rolling FDA filing.

• Source 3 is an industry media report confirming that Intellia is seeking approval for the in vivo CRISPR gene-editing therapy after receiving Phase 3 data, and describing HAELO as the industry’s first in vivo CRISPR gene-editor Phase 3 study to deliver positive results.

• TSO verification conclusion: the three sources agree on the core facts that the Phase 3 trial produced positive results, that this is driving a rolling BLA/FDA submission, and that the therapy targets HAE. There are minor differences in naming, emphasis, and certain trial details, but no direct contradictions.

Shared confirmed facts:

1. Intellia Therapeutics announced lonvo-z Phase 3 results on April 27, 2026.

2. The therapy is intended to treat hereditary angioedema (HAE).

3. HAELO is a Phase 3 clinical trial, and the results were positive.

4. The company has initiated a rolling BLA submission to the U.S. FDA or is seeking approval.

5. All three sources describe this as an important milestone for the in vivo CRISPR / in vivo gene-editing field.

Main differences or variations:

1. The drug name is presented differently: Source 1 uses “lonvo-z (formerly known as NTLA-2002)”; Source 2 uses “lonvoguran ziclumeran (lonvo-z)”; Source 3 refers more generally to “in vivo CRISPR gene editing therapy” without expanding the alias. This is a naming variation rather than a clear contradiction.

2. The strength of the results description varies slightly: Source 1 explicitly says the primary endpoint and all key secondary endpoints were met; Source 2 confirms only the primary endpoint; Source 3 summarizes the outcome as “positive outcomes.” In strict reporting, Source 1’s more complete press-release wording should be used, while noting that the other two sources did not mention all key secondary endpoints.

3. The level of trial-detail disclosure differs: Source 2 mentions randomization of 80 participants, while Sources 1 and 3 do not. Based on the supplied sources, that figure cannot be independently confirmed as complete subject information or merely an added media detail.

4. The milestone framing differs: Source 1 calls it a “global first for in vivo gene editing,” while Source 3 describes it as the industry’s first Phase 3 study of an in vivo CRISPR-based gene editor to produce positive results. Both are ways of emphasizing an industry first, but the wording is not identical and cannot be confirmed as fully equivalent from the sources provided.

Background and analysis:
The significance of lonvo-z meeting its Phase 3 endpoints is that it moves “in vivo CRISPR” from an early concept into late-stage clinical validation. All three sources place the news in the context of an FDA approval pursuit, indicating that the program has entered a critical regulatory submission stage. Based on the confirmed facts, the most important takeaways are that the trial met its preset endpoints, the company is simultaneously advancing a rolling BLA, and the result is widely viewed as a milestone for in vivo gene editing. However, more specific efficacy magnitude, long-term safety, pricing, launch timing, and other details were not provided in the supplied sources and cannot be confirmed from them. Information about a possible launch in the first half of 2027 was not mentioned by any of the three sources and therefore cannot be treated as established fact.

Three-source summary:

• Source 1: The company disclosed positive topline data, explicitly stating that the trial met the primary and key secondary endpoints and that a rolling BLA submission has begun.

• Source 2: Emphasizes that the trial met its primary endpoint and says the company is accelerating its FDA filing.

• Source 3: Highlights that this is the first in vivo CRISPR gene editor to deliver positive late-stage results and notes that Intellia is seeking FDA approval.

Conclusion:
Taken together, the three sources confirm that Intellia’s lonvo-z produced positive results in the HAELO Phase 3 trial and has entered the rolling BLA submission phase with the FDA. This development is jointly viewed as an important milestone for in vivo CRISPR gene editing; however, launch timing, the full magnitude of efficacy, and finer regulatory timing details were not mentioned in the sources and cannot be confirmed.

SOURCE INFORMATION

• Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

• Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture

• Intellia heads to FDA after notching first late-stage win for in vivo gene editor